EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteers

Vishal Goyal iD, Edrich Krantz, Francois Simon iD, Anouk Neven iD, Johanna Eriksson iD, Amaria Saayman, Nabila Ibnou Zekri Lassout, Mathieu Louis, Stephen Robinson iD, Abhijit Deshmukh, Amit Antarkar, Carol Ruffell iD und 6 weitere

Clinical and Translational Science · 2024

DOI: 10.1111/cts.13756 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Vishal Goyal und 17 weiteren Autor:innen. Beteiligte Einrichtung: Drugs for Neglected Diseases Initiative, New York, New York, USA. Hauptthemen laut MEDLINE: Flucytosine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European and Developing Countries Clinical Trials Partnership Association (EDCTP2) programme supported by the European Union, Médecins Sans Frontières International, Swiss Agency for Development and Cooperation (SDC), Switzerland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The opportunistic fungal infection cryptococcal meningoencephalitis is a major cause of death among people living with HIV in sub‐Saharan Africa. We report pharmacokinetic (PK) and safety data from a randomized, four‐period crossover phase I trial of three sustained‐release (SR) oral pellet formulations of 5‐flucytosine conducted in South Africa. These formulations were developed to require less frequent administration, to provide a convenient alternative to the current immediate release (IR) formulation, A. Formulations B, C, and D were designed to release 5‐flucytosine as a percentage of the nominal dose in vitro. We assessed their safety and PK profiles in a single dose (1 × 3000 mg at 0 h), relative to commercial IR tablets (Ancotil 500 mg tablets; 3 × 500 mg at 0 h and 3 × 500 mg at 6 h) in healthy, fasted participants. Forty‐two healthy participants were included. All treatments were well‐tolerated. The primary PK parameters, maximum observed plasma concentration ( C max ) and area under the concentration‐time profiles, were significantly lower for the SR formulations than for the IR tablets, and the geometric mean ratios fell outside the conventional bioequivalence limits. The median maximum time to C max was delayed for the SR pellets. Physiologically‐based PK modeling indicated a twice‐daily 6400 mg dose of SR formulation D in fasted condition would be optimal for further clinical development. This regimen is predicted to result in a rapid steady‐state plasma exposure with effective and safe trough plasma concentration and C max values, within the therapeutic boundaries relative to plasma exposure after four times per day administration of IR tablets (PACTR202201760181404).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FlucytosineHumansBiological AvailabilityHealthy VolunteersCross-Over StudiesDelayed-Action PreparationsTabletsDrug ImplantsAdministration, Oral

Substanzen

FlucytosineDelayed-Action PreparationsTabletsDrug Implants

Autor:innen und Institutionen

  • Drugs for Neglected Diseases Initiative, New York, New York, USA.
  • FARMOVS, Bloemfontein, South Africa.
  • Drugs for Neglected Diseases Initiative, Geneva, Switzerland.
  • Luxembourg Institute of Health, Strassen, Luxembourg.
  • Pharmetheus, Uppsala, Sweden.
  • Viatris, Hyderabad, India.

ORCID-Profile: Vishal Goyal, Francois Simon, Anouk Neven, Johanna Eriksson, Stephen Robinson, Carol Ruffell, Aljosa Celebic, Henri Caplain, Jean-Yves Gillon, Isabela Ribeiro

Förderung

  • European and Developing Countries Clinical Trials Partnership Association (EDCTP2) programme supported by the European Union
  • Médecins Sans Frontières International
  • Swiss Agency for Development and Cooperation (SDC), Switzerland
  • European Commission
  • Direktion für Entwicklung und Zusammenarbeit

Zitieren

APA

Goyal, V., Krantz, E., Simon, F., Neven, A., Eriksson, J., Saayman, A., Ibnou Zekri Lassout, N., Louis, M., Robinson, S., Deshmukh, A., Antarkar, A., Ruffell, C., Victor, S., Chenel, M., Celebic, A., Caplain, H., Gillon, J. Y., & Ribeiro, I. (2024). Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteers. Clinical and Translational Science. https://doi.org/10.1111/cts.13756

Vancouver

Goyal V, Krantz E, Simon F, Neven A, Eriksson J, Saayman A, et al. Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteers. Clinical and Translational Science. 2024. doi:10.1111/cts.13756

BibTeX
@article{Goyal2024,
  author = {Goyal, Vishal and Krantz, Edrich and Simon, Francois and Neven, Anouk and Eriksson, Johanna and Saayman, Amaria and Ibnou Zekri Lassout, Nabila and Louis, Mathieu and Robinson, Stephen and Deshmukh, Abhijit and Antarkar, Amit and Ruffell, Carol and Victor, Sarika and Chenel, Marylore and Celebic, Aljosa and Caplain, Henri and Gillon, Jean-Yves and Ribeiro, Isabela},
  title = {Bioavailability of three novel oral, sustained‐release pellets, relative to an immediate‐release tablet containing 500 mg flucytosine: A randomized, open‐label, crossover study in healthy volunteers},
  journal = {Clinical and Translational Science},
  year = {2024},
  doi = {10.1111/cts.13756}
}
Kostenlos starten →